{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:48:55Z","timestamp":1790887735660,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T00:00:00Z","timestamp":1625961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Eliglustat, an oral substrate reduction therapy, is approved for eligible adults with Gaucher disease type 1. In the Phase 3 ENGAGE trial of previously untreated adults with Gaucher disease type 1, eliglustat\u2010treated patients had statistically significant improvements in organ volumes and hematologic parameters compared with placebo in the 9\u2010month primary analysis. We report final outcomes by time on eliglustat among all patients who participated in the ENGAGE trial and extension. No patient deteriorated clinically or withdrew due to adverse events; 39\/40 patients entered the open\u2010label extension period and 34\/40 (85%) remained in the trial until completion or switching to commercial eliglustat after its approval (2.3\u20136\u2009years). Clinically meaningful improvements in Gaucher disease manifestations were seen in all patients concomitant with reductions in pathological lipid substrate levels (glucosylceramide and glucosylsphingosine). Among patients with 4.5\u2009years of eliglustat exposure, mean spleen volume decreased by 66% (from 17.1 to 5.8 multiples of normal [MN], <jats:italic>n<\/jats:italic>\u00a0=\u00a013), mean liver volume decreased by 23% (from 1.5 to 1.1 MN, <jats:italic>n<\/jats:italic>\u00a0=\u00a013), mean hemoglobin increased 1.4\u00a0g\/dl (from 11.9 to 13.4\u00a0g\/dl, <jats:italic>n<\/jats:italic>\u00a0=\u00a012), mean platelet count increased by 87% (from 67.6 to 122.6\u2009\u00d7\u200910<jats:sup>9<\/jats:sup>\/L, <jats:italic>n<\/jats:italic>\u00a0=\u00a012), median chitotriosidase decreased by 82% (from 13\u2009394 to 2312\u2009nmol\/h\/ml, <jats:italic>n<\/jats:italic>\u00a0=\u00a011), median glucosylceramide decreased by 79% (from 11.5 to 2.4\u2009\u03bcg\/ml, <jats:italic>n<\/jats:italic>\u00a0=\u00a011), median glucosylsphingosine decreased by 84% (from 518.5 to 72.1\u2009ng\/ml, <jats:italic>n<\/jats:italic>\u00a0=\u00a010), and mean spine T\u2010score increased from \u22121.07 (osteopenia) to \u22120.53 (normal) (<jats:italic>n<\/jats:italic>\u00a0=\u00a09). The magnitude of improvement in Gaucher disease manifestations and biomarkers over time was similar among the full trial cohort. Eliglustat was well\u2010tolerated and led to clinically significant improvements in previously untreated patients with Gaucher disease type 1 during 4.5\u2009years of treatment.<\/jats:p>","DOI":"10.1002\/ajh.26276","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T17:27:35Z","timestamp":1624469255000},"page":"1156-1165","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Clinical outcomes after 4.5\u2009years of eliglustat therapy for <scp>Gaucher<\/scp> disease type 1: Phase 3 <scp>ENGAGE<\/scp> trial final results"],"prefix":"10.1002","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-6421","authenticated-orcid":false,"given":"Pramod K.","family":"Mistry","sequence":"first","affiliation":[{"name":"Yale University School of Medicine  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8774-850X","authenticated-orcid":false,"given":"Elena","family":"Lukina","sequence":"additional","affiliation":[{"name":"National Research Center for Hematology  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadhami","family":"Ben Turkia","sequence":"additional","affiliation":[{"name":"H\u00f4pital La Rabta  Tunis Tunisia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suma P.","family":"Shankar","sequence":"additional","affiliation":[{"name":"Emory University  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Baris Feldman","sequence":"additional","affiliation":[{"name":"The Genetics Institute, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwan","family":"Ghosn","sequence":"additional","affiliation":[{"name":"H\u00f4tel\u2010Dieu de France University Hospital  Beirut Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Mehta","sequence":"additional","affiliation":[{"name":"The Royal Free Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seymour","family":"Packman","sequence":"additional","affiliation":[{"name":"UCSF School of Medicine  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Lau","sequence":"additional","affiliation":[{"name":"New York University School of Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Petakov","sequence":"additional","affiliation":[{"name":"Clinical Center of Serbia Belgrade University Medical School  Belgrade Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[{"name":"Jewish General Hospital  Montreal Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8047-5011","authenticated-orcid":false,"given":"Manisha","family":"Balwani","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mt. Sinai Hospital  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumita","family":"Danda","sequence":"additional","affiliation":[{"name":"Christian Medical College  Vellore India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgueniy","family":"Hadjiev","sequence":"additional","affiliation":[{"name":"University Hospital Alexandrovska  Sofia Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Ortega","sequence":"additional","affiliation":[{"name":"OCA Hospital  Monterrey Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith C.","family":"Foster","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J. M.","family":"Gaemers","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Judith","family":"Peterschmitt","sequence":"additional","affiliation":[{"name":"Sanofi Genzyme  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,11]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"OMMBID: The Online Metabolic and Molecular Bases of Inherited Disease","author":"Grabowski GA","year":"2013"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.3021"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21368"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.5858\/2008-132-851-GDROTL"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105233242104"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.GIM.0000153660.88672.3C"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2020.12.295"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2013.2"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2017.01.006"},{"key":"e_1_2_8_11_1","unstructured":"CERDELGA\u2122 (eliglustat) [package insert]. Genzyme Corporation A Sanofi Company Waterford Ireland; 2018.http:\/\/www.cerdelga.com\/pdf\/cerdelga_prescribing_information.pdf. Accessed December 04 2018."},{"key":"e_1_2_8_12_1","unstructured":"CERDELGA\u2122 84 mg capsules. Summary of Product Characteristics. Genzyme Therapeutics Oxfordshire England; 2018.https:\/\/www.medicines.org.uk\/emc\/product\/2615\/smpc. Accessed May 01 2019."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1085-6"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61841-9"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-273151"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.459"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2017.12.001"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-293902"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25300"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2014.04.002"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24877"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-758409"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00256-007-0425-0"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.06.1410"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-600270"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1508808"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2007.04.002"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2004.07.009"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2016.10.008"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-012-9528-4"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09175.x"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01150-6"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-010-9175-6"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01646850"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21721"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-352971"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1003308107"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61522-6"},{"key":"e_1_2_8_39_1","first-page":"59","article-title":"Prevalence and management of Gaucher disease","volume":"2","author":"Burrow TA","year":"2011","journal-title":"Pediatr Health Med Ther"},{"key":"e_1_2_8_40_1","first-page":"81","article-title":"Imiglucerase in the treatment of Gaucher disease: a history and perspective","volume":"6","author":"Deegan PB","year":"2012","journal-title":"Drug Des Devel Ther"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2012.00106"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25875"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.26276","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.26276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T12:40:19Z","timestamp":1693140019000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.26276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,11]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["10.1002\/ajh.26276"],"URL":"https:\/\/doi.org\/10.1002\/ajh.26276","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,11]]},"assertion":[{"value":"2021-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}